Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Cervical Cancer
How does your approach to the primary treatment of glassy cell carcinoma of the cervix differ from the primary treatment of squamous cell or adenocarcinoma of the cervix?
Answer from: at Community Practice
No difference.
Sign In
or
Register
to read more
13922
Related Questions
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
How would you utilize brachytherapy boost in addition to EBRT for HPV-dependent invasive squamous cell carcinoma present as a large pelvic side wall mass, presumed to be of cervix primary, albeit the negative biopsies of the cervix?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
What is your preferred management for persistent viable cervical tumor 6 months after high-quality chemoradiation with KEYNOTE A-18 regimen for locally advanced cervical cancer?
Would you ever consider pelvic exenteration followed by SBRT for a patient with recurrent cervical cancer (s/p chemoRT) who has disease only in the central pelvis and in a single hilar lymph node?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?
Would you consider adding pembrolizumab to chemoradiation for locally advanced cervical cancer in a patient with cirrhosis (elevated bilirubin (<3x ULN) and mild LFT elevation), ascites, and signs of portal hypertension?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
Do you perform pap smears as part of the surveillance of patients with a history of cervical or vaginal cancers who had radiation as part of their treatment?